A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases (NCT06136884)
A Phase 1, Open-Label, Dose-escalation and Dose-Expansion Study Evaluating AO-252, a Protein-Protein Interaction Inhibitor of TACC3, in Patients With Advanced Solid Tumors With or Without Brain Metastases
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Who can join: Review the eligibility criteria below.
Location: Karmanos Cancer Institute — Detroit, Michigan
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Karmanos Cancer Institute — Detroit, Michigan
- Oklahoma Univeristy — Oklahoma City, Oklahoma
- Hollings Cancer Center - MUSC — Charleston, South Carolina
- Mary Crowley Cancer Research — Dallas, Texas
- The University of Texas M.D. Anderson Cancer Center — Houston, Texas
- Next Oncology -Virginia — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (214) 205-5746
Email: rfrnka@coiledtx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor Malignancies
- Exploring the Feasibility of Cerebrospinal Fluid (CSF) and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and Primary Central Nervous System (CNS) Tumours: A Pilot Study — Toronto, Ontario
- Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors — Denver, Colorado
- Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) — Tucson, Arizona
- A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies — La Jolla, California
- Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors — Scottsdale, Arizona
Explore by condition: All Solid Tumor Malignancies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.